RxDoctor Payments Data

Beatrice Onyeador, MD

Internal Medicine · Clifton, NJNPI 1114969870

Payments from drug & device makers

$387in general payments, 2019–2025

Across 12 payments — averaging $32.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$133
  • AbbVie$101
  • Arbor Pharmaceuticals, Inc.$37
  • Aerin Medical Inc.$31
  • Boehringer Ingelheim$30
  • Bayer$20
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$28574%
  • Education$10226%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$387 in reported general payments places this provider in the 50th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$161,971
Medicare patients
41
Services billed
413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$85,619
JardianceEmpagliflozin78$78,574
LinzessLinaclotide69$67,871
FarxigaDapagliflozin Propanediol66$66,134
JanuviaSitagliptin Phosphate67$58,085
Diclofenac Sodium50$48,652
JanumetSitagliptin Phos/Metformin Hcl41$47,249
VraylarCariprazine Hcl32$45,218
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$36,049
MounjaroTirzepatide11$19,817
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$19,183
TradjentaLinagliptin18$18,405
RexultiBrexpiprazole14$17,223
Tresiba Flextouch U-100Insulin Degludec18$16,284
Arnuity ElliptaFluticasone Furoate27$13,747

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Vraylar$101$113,089101 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Synjardy Xr$30$109,908127 claims
Novo NordiskOzempic$16$85,61975 claims
Lilly USA, LLCMounjaro$19$19,81711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Clifton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →